Rapid Screening of Drug Paraphernalia by DART-HRMS Using the Seized Drug Suite

Rapid Screening of Drug Paraphernalia by DART-HRMS Using the Seized Drug Suite — Summary

Importance of the topic

The analysis of residual material from used syringes and other drug paraphernalia provides near-real-time chemical intelligence on local drug markets, polydrug use and adulterants that pose acute health risks. Conventional chromatographic screening workflows (GC-/LC-MS with MSn) are robust but relatively slow, limiting throughput for large surveillance projects. Rapid, chromatography-free approaches such as DART coupled with high-resolution mass spectrometry (DART-HRMS) can deliver targeted and untargeted screening in seconds, enabling faster public-health responses, harm-reduction interventions and laboratory triage for confirmatory testing.

Aim and overview of the study

The project evaluated a rapid screening workflow for drugs of abuse and adulterants in used syringes collected within the ESCAPE (European Syringe Collection and Analysis Project Enterprise) pilot in Cologne, Germany. The objectives were to compare DART-HRMS analyzed with the Seized Drug Suite versus routine LC-MSn screening using the Toxtyper workflow, assess concordance, document typical findings in syringe residues, and identify strengths and limitations of DART-HRMS as a high-throughput screening tool.

Sample collection and preparation

- Total samples: 299 syringe samples collected from five harm-reduction / consumption service locations in Cologne.
- Sample types included syringes with and without needles; residues were extracted (typical extraction solvents included acetonitrile or methanol, ~1 mL) and diluted (reported dilutions 1:10–1:20). Ultrasonication (≈10 min) and storage at −20 °C were used in sample handling.
- Extracts were applied to QuickStrip HTS sample cards and allowed to dry prior to DART analysis. A metal holder for QuickStrip facilitated automated DART sampling.

Used instrumentation (Použitá instrumentace)

- DART-HRMS platform: Bruker QTOF with DART JumpShot® (positive ion mode). Operational settings included helium as run gas, nitrogen as standby, source temperature ~275 °C, linear scanning at 0.5 mm/s over ~4.5 mm, and AutoMS/MS acquisition (~9 Hz) with m/z scan range 30–1000.
- LC-MSn screening (reference method): Dionex UltiMate 3000 LC with Acclaim RSLC 120 C18 (2.1 × 100 mm, 2.2 µm) using an 11 min gradient; eluents buffered with 2 mM ammonium formate/formic acid in water and acetonitrile. MSn performed on Bruker amaZon speed with Apollo ESI source, UltraScan acquisition and AutoMSn (n = 3) for confirmatory spectral matching.
- Data processing: Automated reporting and compound identification were performed in Bruker DataAnalysis. Seized Drug Suite used exact mass + MS2 spectral matching against an internal library (≈400 entries) plus the MMHW LC-HR-MS/MS Wiley library (~5,000 entries). Toxtyper identification relied on retention time and MS2/MS3 spectral comparison against an in-house library (~1,475 entries).

Methodology and workflow

- Rapid workflow: extraction → dilution → spot onto QuickStrip → solvent drying → DART-HRMS analysis (20–60 seconds per sample) → automated Seized Drug Suite processing for targeted/untargeted identifications.
- Comparative workflow: LC-MSn (10–25 minutes per run plus data processing) using Toxtyper automated reporting; used as the reference for detailed compound characterization and detection of low-abundance metabolites/degradation products.

Main results and discussion

- Concordance: Overall, the DART-HRMS Seized Drug Suite produced results consistent with LC-MSn for approximately 71.2% of samples (major active ingredient detected by both methods while excluding minor degradation products/adjuvants).
- Category breakdown: A subset of samples showed low-intensity discrepancies (compounds detected by LC-MSn at low signal intensity but not by DART-HRMS), and some samples had inconsistent results where the main active ingredient was not identified by DART-HRMS. This behavior is attributed to variable residue abundance, dilution strategy and differences in ionization efficiency and matrix effects between techniques.
- Frequently detected compounds: Heroin and cocaine were the most frequently detected parent drugs. Common cutting agents such as caffeine and paracetamol were also often observed. Additional detections included amphetamine, MDMA, methylphenidate and methadone in small numbers.
- Notable findings: The synthetic cannabinoid ADB-4en-PINACA was identified in nine samples across four collection sites. In some cases Toxtyper (LC-MSn) detected cocaine metabolites (methylecgonine, norcocaine) and cocaethylene; DART-HRMS sometimes failed to identify low-abundance markers such as ADB-4en-PINACA or certain poppy alkaloids (heroin markers) likely due to low ion signal.
- Analysis time and throughput: DART-HRMS with the Seized Drug Suite achieved more than a 20-fold reduction in overall analysis time compared with conventional LC-MSn screening, making it highly suited for high-throughput triage and monitoring.

Key strengths and limitations

- Strengths:

• Extremely fast analysis (seconds per sample) enabling high-throughput screening and rapid community monitoring.
• Chromatography-free workflow simplifies sample handling and reduces bottlenecks in routine screening labs.
• Combination of exact mass and MS/MS spectral matching supports both targeted and untargeted identification with library support.

- Limitations:

• Lower sensitivity for low-abundance compounds relative to LC-MSn in some matrices; compounds present at trace levels or heavily ion-suppressed may be missed.
• Differences in ionization efficiencies and matrix effects limit quantitative comparison across techniques.
• Chromatographic separation advantages (e.g., isobar separation, detailed metabolite profiling) are not available, so confirmatory LC-QTOF or LC-MSn is recommended for cases requiring definitive identification or isomer differentiation.

Practical benefits and applications

- DART-HRMS paired with automated spectral matching is well suited as a front-line screening and triage tool in forensic and public-health laboratories, enabling rapid identification of prevalent drugs and adulterants in paraphernalia.
- The methodology supports surveillance programs like ESCAPE by providing timely, local chemical data that supplement self-reported and survey-based information about drug use patterns.
- Use cases include harm-reduction monitoring, early-warning detection of novel psychoactive substances, and workload reduction by prioritizing samples for confirmatory analysis.

Future trends and potential uses (Budoucí trendy a možnosti využití)

- Optimization of extraction and dilution protocols to improve detection of low-abundance residues and reduce false negatives in DART workflows.
- Expansion and curation of high-quality MS2 spectral libraries to enhance confidence in untargeted identifications, especially for novel synthetic cannabinoids and designer drugs.
- Integration of machine-learning assisted spectral interpretation and automated triage rules to streamline decision-making for follow-up confirmatory testing.
- Hybrid workflows combining DART-HRMS screening with selective LC-QTOF confirmation to balance throughput and analytical depth in routine surveillance programs.

Conclusion

DART-HRMS combined with the Seized Drug Suite demonstrated strong potential as a rapid screening tool for drug paraphernalia, achieving substantial time savings and good concordance with routine LC-MSn screening for the majority of samples. While DART-HRMS is not a complete replacement for chromatographic confirmatory techniques—particularly for low-abundance compounds and isobaric/isomeric differentiation—it is highly effective as a high-throughput triage method and an untargeted screening platform for public-health and forensic monitoring initiatives.

References

No formal literature list was provided in the source material. The study results and instrumentation details are those reported from the ESCAPE project analyses and the Bruker Seized Drug Suite / Toxtyper comparative evaluation.